Here are seven updates from gastroenterology companies and practices from the past week:
RDD Pharma entered into a letter of intent to acquire Naia Rare Diseases in a move to boost its gastrointestinal drug pipeline.
Abbvie committed the fourth largest corporate bond sale of all time when it sold $30 billion worth of bonds to partially finance its $83 billion takeover of Allergan.
Becker's ASC Review revisited the Atlanta Gastroenterology Associates and Frazier Healthcare Partners deal (almost) a year later to present insights into what's happened since. Read more.
CRH Medical continues to bring in the revenue in 2019, posting $30.4 million in third-quarter revenues, up from $28.7 million in the same period last year. Read more.
Exact Sciences closed its $2.8 billion acquisition of Genomic Health Nov. 8, securing rights to Genomic's diagnostic oncology test, Oncotype DX.
Boston Medical Center is studying how Motus GI's Pure-Vu System affects bowel preparation in a clinical setting.
Danville, Pa.-based Geisinger Health and Pittsburgh-based Highmark Health broke ground on a medical clinic in Lock Haven, Pa.